 BOTHELL, Wash., June 23, 2021 GLOBE NEWSWIRE -- Cocrystal Pharma, Inc. Nasdaq: COCP Cocrystal or the Company, a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces the completion of IND-enabling studies with its potent, broad-spectrum PB2 inhibitor CC-42344 for the treatment of seasonal and pandemic influenza A and plans to initiate Phase 1 clinical development of CC-42344 in the third quarter of 2021. 